Proficio Capital Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $288K | Buy |
882
+74
| +9% | +$24.1K | 0.02% | 328 |
|
|
2025
Q1 | $218K | Buy |
+808
| New | +$218K | 0.02% | 354 |
|
|
2024
Q4 | – | Sell |
-744
| Closed | -$205K | – | 365 |
|
|
2024
Q3 | $205K | Sell |
744
-838
| -53% | -$230K | 0.02% | 271 |
|
|
2024
Q2 | $384K | Sell |
1,582
-464
| -23% | -$113K | 0.04% | 203 |
|
|
2024
Q1 | $306K | Buy |
+2,046
| New | +$306K | 0.03% | 240 |
|
|
2019
Q3 | – | Sell |
-74
| Closed | -$5K | – | 188 |
|
|
2019
Q2 | $5K | Sell |
74
-4
| -5% | -$270 | ﹤0.01% | 1183 |
|
|
2019
Q1 | $7K | Buy |
78
+2
| +3% | +$179 | ﹤0.01% | 987 |
|
|
2018
Q4 | $6K | Sell |
76
-26
| -25% | -$2.05K | ﹤0.01% | 813 |
|
|
2018
Q3 | $9K | Hold |
102
| – | – | ﹤0.01% | 814 |
|
|
2018
Q2 | $10K | Buy |
102
+40
| +65% | +$3.92K | ﹤0.01% | 815 |
|
|
2018
Q1 | $7K | Buy |
62
+24
| +63% | +$2.71K | ﹤0.01% | 908 |
|
|
2017
Q4 | $5K | Hold |
38
| – | – | ﹤0.01% | 954 |
|
|
2017
Q3 | $4K | Hold |
38
| – | – | ﹤0.01% | 976 |
|
|
2017
Q2 | $3K | Hold |
38
| – | – | ﹤0.01% | 1021 |
|
|
2017
Q1 | $3K | Buy |
38
+7
| +23% | +$553 | ﹤0.01% | 1053 |
|
|
2016
Q4 | $1K | Sell |
31
-20
| -39% | -$645 | ﹤0.01% | 982 |
|
|
2016
Q3 | $3K | Buy |
51
+45
| +750% | +$2.65K | ﹤0.01% | 793 |
|
|
2016
Q2 | $0 | Buy |
+6
| New | – | ﹤0.01% | 1007 |
|
|
2016
Q1 | – | Sell |
-13
| Closed | -$1K | – | 1043 |
|
|
2015
Q4 | $1K | Buy |
+13
| New | +$1K | ﹤0.01% | 743 |
|